A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Publication date: May 10, 2019

The primary objective of this study is to evaluate the safety, tolerability of single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS). The secondary objective of the study is to characterize the pharmacokinetic profile of BIIB100.

Concepts Keywords
ALS Significant cognitive impairment
Amyotrophic Lateral Sclerosis Untreated major depression
Anemia Unstable psychiatric illness
Biogen ALS
Cachexia Cachexia severe anemia
Cognitive Impairment Drugs
Depression Benzothiazoles
Escorial Riluzole
Neurology Biogen
Pharmacokinetic Pharmacokinetics
Psychiatric Illness Pharmacodynamics
Psychosis
Suicidal Ideation
Suicide
Tolerability
Vital Capacity

Semantics

Type Source Name
disease MESH Amyotrophic Lateral Sclerosis
disease DOID Amyotrophic Lateral Sclerosis
gene UNIPROT IGFALS
gene UNIPROT SOD1
drug DRUGBANK Riluzole
drug DRUGBANK Edaravone
disease MESH sitting position
disease MESH anemia
disease DOID anemia
disease MESH cognitive impairment
disease MESH psychosis
disease MESH suicidal ideation
disease MESH suicide
disease MESH depression
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Sclerosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *